<DOC>
	<DOC>NCT02645734</DOC>
	<brief_summary>In this double clinical trial 132 patient with the history of DME (Diabetic Macular Edema) to receive intravitreous bevacizumab at a dose of 1.25mg (44 patient) , ziv-aflibercept at dose of 1.25 mg (44 patient) , ziv-aflibercept at dose of 2.5 mg (44 patient) . The study drugs were administered as often as every 4 weeks for 3 months.monitoring of best-corrected visual acuity, CST ( Central Subfield Thickness) by OCT (Optical coherence tomography) was done from base line ,4 weeks, 8weeks after injection.</brief_summary>
	<brief_title>The Effect of Bevacizumab and Ziv-aflibercept in Diabetic Macular Edema</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>The patient at least 18 years old had type 1 or 2 diabetes who presented with Central DME involvement (defined as retinal thickening involving 1mm central sub field thickness(CCT) Have at least a BCVA ( best corrected visual acuity) between 20/50 to 20/320 Snellen equivalent Have received to antiVEGF( anti vascular endothelial growth factor) and laser treatment within the previous 3 months Uncontrolled glaucoma/uncontrolled diabet , high risk PRP(panretinal photocoagulation), one eye Prior treatment with intravitreal or peribulbar injection and laser therapy during the last 3 months Substantial cataract, history of uveitis Macular edema due to a cause other than DME VMT(Vitreomacular traction ) and ERM (epiretinal membrane)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>